Clinical trial
Study of Intravenous BCX-1777 in Relapsed or Refractory Aggressive T-Cell…
NCT00035022 · BioCryst Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00035022 |
|---|---|
| Title | Study of Intravenous BCX-1777 in Relapsed or Refractory Aggressive T-Cell Leukemias or Lymphomas |
| Official title | Phase I-II Study of Intravenous BCX-1777 in Relapsed or Refractory Aggressive (High Grade) T-Cell Malignancies |
| Lead sponsor | BioCryst Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Leukemia, Lymphocytic, Lymphoma |
| Intervention type | Drug |
| Interventions | BCX-1777 |
| Enrollment | 71 |
| Start date | Aug 1, 2001 |
| Completion | Mar 1, 2004 |
| First posted | May 3, 2002 |
| Last update posted | Jan 13, 2006 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: